NCT04885413 2021-08-23An Open-label, Single Arm, Phase II Trial of Niraparib in Combination With Anti-PD1（Programmed Cell Death Protein 1） Antibody in Recurrent/ Advanced Stage Endometrial Cancer PatientsSun Yat-sen UniversityPhase 2 Unknown37 enrolled